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Background: Parkinson’s disease (PD) affects about
1% of the over 60 population and is characterized by
a combination of motor symptoms (rest tremor,
bradykinesia, rigidity, postural instability, stooped
posture and freezing of gait [FoG]) and non-motor
symptoms (including psychiatric and cognitive disor-
ders). Given that the loss of dopamine in the striatum
is the main pathochemical hallmark of PD, pharma-
cological treatment of the disease has focused on
restoring dopaminergic neurotransmission and thus
improving motor symptoms. However, the currently
licensed medications have several major limitations.
Firstly, dopaminergic medications modulate all the
key steps in dopamine transmission other than the
most powerful determinant of extracellular dopamine
levels: the activity of the presynaptic dopamine trans-
porter. Secondly, other monoaminergic neurotrans-
mission systems (ie noradrenergic, cholinergic and
glutamatergic systems are altered in PD and may be
involved in a variety of motor and non-motor symp-
toms. Thirdly, today’s randomized clinical trials are
primarily designed to assess the efﬁcacy and safety of
treatments for motor ﬂuctuations and dyskinesia.
Fourthly, there is a need for disease- modifying treat-
ments (DMTs) that slow disease progression and
reduce the occurrence of the very disabling disorders
seen in late-stage PD.
Objective: To systematically review a number of
putative pharmacological options for treating the
main impairments in late-stage PD (ie gait disorders,
cognitive disorders and behavioural disorders such as
apathy).
Methods: We searched the PubMed database up
until July 2013 with logical combinations of the1640following search terms: “Parkinson’s disease”, “gait”,
“cognition”, “apathy”, “advanced stage”, “modula-
tion”, “noradrenergic”, “cholinergic”, “glutamater-
gic” and “neurotransmission”.
Results: In patients undergoing subthalamic nu-
cleus stimulation, the potentiation of noradrenergic
and dopaminergic transmission by methylphenidate
improves gait and FoG and may relieve apathy.
However, the drug failed to improve cognition in this
population. Potentiation of the cholinergic system by
acetylcholinesterase inhibitors (which are licensed for
use in dementia) may reduce pre-dementia apathy and
falls. Modulation of the glutamatergic system by an
N-methyl-D-aspartate receptor antagonist did not
improve gait and dementia but may have reduced
axial rigidity. A number of putative DMTs have been
reported.
Discussion: Novel therapeutic strategies should
seek to reduce the appearance of the very disabling
disorders observed in late-stage PD. Dopamine and/or
noradrenaline transporter inhibitors, anticholinester-
ase inhibitors, Peroxisome-proliferator-activated-re-
ceptor-agonists and iron chelators should at least be
investigated as putative DMTs by applying a delayed-
start clinical trial paradigm to a large population
Conclusions: There is a need for more randomized
clinical trials of treatments for late-stage PD. (Clin
Ther. 2013;35:1640–1652) & 2013 Elsevier HS Jour-
nals, Inc. All rights reserved.Volume 35 Number 10
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INTRODUCTION
Parkinson’s disease (PD) is the second most frequent
neurodegenerative disorder worldwide and affects
about 1% of the over 60s.1 The disease is chara-
cterized by a combination of rest tremor, bradykinesia,
rigidity and gait disorders. However, the clinical
spectrum also encompasses non-motor symptoms,
including behavioural disorders (such as apathy) and
cognitive disorders.2 The core neuropathological
features of PD are the loss of dopaminergic neurons
in the substantia nigra and the deposition of iron and
cytoplasmic protein aggregates (Lewy bodies) inside
neurons. Given that the loss of dopamine in the
striatum is the main pathochemical hallmark of PD,
pharmacological treatment of the disease has been
focused on restoring dopaminergic neurotrans-
mission.3 The dopamine precursor levodopa remains
the “gold standard” treatment for PD; it improves the
patient’s motor functions, activities of daily living and
quality of life. However, levodopa also has several
pharmacokinetic drawbacks (notably its short half-
life). Hence, the chronic administration of levodopa
required for advanced PD is frequently associated with
the development of levodopa-related motor ﬂuctua-
tions and dyskinesia. The prevalence of these motor
complications ranges from 40% to 50% after 4 to 6
years of treatment.4,5 Inhibitors of the dopamine-
metabolizing enzymes catechol-O-methyltransferase
and monoamine oxidase-B (MAO-B) have been devel-
oped with a view to prolonging the half-life of
levodopa and thus limiting motor ﬂuctuations. Dop-
amine agonists directly stimulate postsynaptic dopa-
mine receptors in the striatum, in order to decrease the
need for levodopa and limit the appearance of motor
complications.4,6,7 However, the dopamine agonists’
safety proﬁle provides cause for concern, since these
medications may variously induce impulse control
disorders (ICDs), confusion, hallucinations, psychosis,
excessive daytime sleepiness and sleep attacks.4,8 Deep
brain stimulation of the subthalamic nucleus (STN)
(or, to a lesser extent, the internal globus pallidus) is a
proven, very effective means of controlling motor
complications.9 However, the contraindications for
this treatment limit its application to just a small
proportion of PD patients. Continuous, subcutaneousOctober 2013apomorphine infusion is an effective treatment option
for motor ﬂuctuations but again is also only used with
a small proportion of PD patients - probably because
apomorphine is a dopaminergic agonist and the
infusion pump is an external device. Earlier intro-
duction of this treatment should nevertheless be
considered.10 Duodenal levodopa infusion* appears
to be a very effective therapy for motor complications.
However, poor user-friendliness (a heavy, external
pump and the need for gastrostomy) restricts Duodo-
pas to use as a last-line therapy.11 Lastly, a number of
licensed and unlicensed drugs have also been proposed
(often with a low level of scientiﬁc evidence) for the
treatment of non-motor symptoms (for a review, see 12).
The beneﬁcial, long-term effects of currently licensed
medications are often countered by the appearance of
gait, cognitive and behavioural disorders as the disease
progresses. This may prompt institutionalization and
constitutes a public health issue.13,14 The associated gait
disorders are mainly characterized by impaired stride
length regulation and thus a slower walking speed (ie
gait hypokinesia).15 Furthermore, freezing of gait (FoG,
ie a brief, involuntary, episodic absence of (or a marked
reduction in) forward progression of the foot) can also
be prominent.16 Although the disease mechanism
underlying for FoG is not fully understood, several
different factors are clearly involved. Gait disorders
associated with FoG appear to be mainly related to
disease severity and a hypodopaminergic state.17
Optimization of levodopa treatment is the main
therapeutic option under these circumstances.16,17 How-
ever, the option of increasing the levodopa dose may be
signiﬁcantly restricted by (i) the worsening of levodopa-
related motor complications, (ii) induction of confusion
or sleepiness and (iii) progressive loss of efﬁcacy as the
disease worsens. Patients with PD have an almost six-
fold greater risk of developing dementia than age-
matched, healthy controls do.18 In cross-sectional stud-
ies, 30% to 40% of PD patients meet the criteria for
dementia.14 Moreover, a number of longitudinal studies
have revealed that the cumulative incidence of dementia
in patients with PD increases with age and disease
duration and can even reach 80% to 90%.19–21 The
cognitive proﬁle in PD dementia (PDD) differs from that
in Alzheimer’s disease (AD) and is dominated by severe
impairments in attention and in executive and visuo-
spatial functions; in contrast, memory encoding,1641
Clinical Therapeuticslanguage, and orientation in time and space are rela-
tively unaffected.22–25 Early diagnosis of PDD is impor-
tant because cholinesterase inhibitors are efﬁcacious in
this context.26,27 In terms of behavioural disorders,
apathy is characterized by lack of interest, loss of
initiative, diminished motivation, greater effort in per-
forming everyday activities and indifference or ﬂattening
of affect. Apathy is frequently considered to be a
symptom of depression but sometimes occurs in the
absence of a mood disorder.28 Indeed, apathy is
frequent in PD and has an estimated prevalence of
between 13.9% and 60%,29,30 depending on the diag-
nostic criteria applied and whether demented and/or
depressed patients are included. In fact, apathy is more
frequent in late-stage PD and thus the prevalence has
been estimated to be 15% in patients with stable
disease, 30% in ﬂuctuating patients and 56% in
demented patients.31 Schematically, one can consider
at least two different forms of apathy: dopaminergic
apathy (with mesolimbic denervation)32 and late-stage
apathy. The latter is not markedly improved by dop-
aminergic medications and may be predictive of the
occurrence of dementia.33
At present, we lack speciﬁc treatments for these very
disabling disorders of late-stage PD. However, changes
in other monoaminergic neurotransmission systems
(such as the noradrenergic, cholinergic and glutamater-
gic systems) occur in PD as a result of disease pro-
gression and the extension of neurodegeneration.3,34,35
However, most of today’s on-going or planned random-
ized clinical trials of non-dopaminergic drugs have been
designed to assess efﬁcacy in the treatment of motor
ﬂuctuations and dyskinesia.3,36
Here, we review a number of novel symptomatic
treatment options for late-stage disorders: (1) potentia-
tion of noradrenergic and dopaminergic transmission via
inhibition of the norepinephrine transporter (NeT) and
the dopamine transporter (DaT) , (2) potentiation of the
cholinergic system by inhibition of acetylcholinesterase,
(3) modulation of the glutamatergic system and (4) a
number of putative disease-modifying treatments
(DMTs) for reducing the occurrence of these disorders.
SYMPTOMATIC TREATMENT OPTIONS FOR
LATE-STAGE DISORDERS
Norepinephrine and Dopamine Transporter
Inhibition
Neuronal loss in the locus coeruleus (which can be
as high as 70%) leads to a dramatic decrease in the1642norepinephrine content of the brain - second only to
the loss of dopamine production.34 It has been
reported that administration of an alpha-2 adrenergic
antagonist decreased motor handicap in the unilateral
6-hydroxydopamine mouse model of PD.37 The
relationship between norepinephrine depletion and
the symptoms of PD remains to be characterized.
However, norepinephrine is thought to be involved in
FoG,38 since the synthetic precursor L-threo-DOPS
(droxidopa) has particularly beneﬁcial effects.39–41
Methylphenidate (MPD) is a central nervous system
stimulant that is licensed for the treatment of attention
deﬁcit hyperactivity disorder (ADHD) and narcolepsy
in Europe and the USA. The compound blocks
norepinephrine and dopamine reuptake by inhibiting
the presynaptic NeT and DaT 42–44 (the most power-
ful determinant of extracellular dopamine levels)45 -
particularly in the striatum and the prefrontal
cortex.46 Methylphenidate was ﬁrst tested in a very
small cohort of PD patients in 1961. A dose of
between 0.5 and 1 mg/kg/d was associated with an
improvement in voluntary movements and less
rigidity.47 However, MPD ’s effects were mostly
attributed to its impact on mood (ie its euphoriant
action), which was associated with increased restless
and insomnia in some patients. This might explain (at
least in part) why MPD has not been further develo-
ped in PD. In fact, MPD has always been considered
as a treatment for attention disorders, with potentially
valuable effects on cognition and behaviour but not
(at least directly) motor symptoms. The renewed inte-
rest in MPD was prompted by a suggestion that gait
disorders in PD are profoundly inﬂuenced by attention
disorders.
Gait and Axial Disorders
Four open-label studies have assessed the efﬁcacy of
MPD in gait hypokinesia. The ﬁrst study (by Auriel
et al) assessed the effect of acute administration of
MPD (20 mg) in 21 non-demented, non-stimulated PD
patients who were free of major postural or gait
disorders and had stable dopaminergic regimens.48
The researchers observed signiﬁcant improvements in
all gait parameters. The second study (by Nutt et al)
found that 0.2 or 0.4 mg/kg MPD had effects on gait
or on the performance of a tapping task when
administered two hours after the infusion of
levodopa but when not administered alone.44 The
third open-label study (by Pollak et al)49 examined theVolume 35 Number 10
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patients with severe PD during the "off" state. Low-
dose MPD was associated with improvements in all
gait parameters and FoG. Lastly, Devos et al50 decided
to test the effect of high-dose (1 mg/kg) MPD on gait
disorders because low doses of the drug (0.25 mg/
kg) may only occupy half the striatal DaTs in
humans.43 Over a three-month period, MPD was
administered to 17 advanced PD patients undergoing
STN stimulation. Acute administration of MPD (in
both the presence and absence of levodopa) was
associated with a lower number of steps and a lower
test completion time (relative to the “off-drug, on-
stim” condition). Methylphenidate and levodopa re-
duced the parameters to a similar extent and had
additive effects in this population. Twelve of the 17
patients displayed FoG episodes in either the “off
drugs, on-stim” or the “off-stim, on-levodopa” con-
dition. There was a non-signiﬁcant trend towards a
lower number of FoG episodes in the “on-levodopa,
on-MPD” condition. In contrast to previous studies,
chronic administration of high-dose MPD (in both the
presence and absence of dopaminergic medications)
clearly had an effect on gait disorders in advanced PD.
Furthermore, two randomized clinical trials have been
recently performed.51,52 The ﬁrst (performed by Espay
et al) was a six-month, double-blind, placebo-con-
trolled, randomized, single-centre crossover study in
27 PD patients.51 The second (performed by Moreau
et al) was a double-blind, placebo-controlled,
randomized, multicentre trial in 69 PD patients.52
The two studies had similar objectives and provided
complementary information, even though the
respective effects of MPD on gait impairments
differed. Espay et al recruited advanced-stage PD
patients with gait impairments (Hoehn & Yahr stage
III and a score of 1 or more for item 29 of the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS) part III).
Demented individuals or those undergoing STN stim-
ulation were excluded. The included patients were
randomized to 12 weeks of treatment with either
placebo or 1 mg/kg MPD. Relative to placebo, MPD
was associated with only a slight improvement in the
composite gait score in the “off- levodopa” condition
and did not improve the FoG questionnaire (FoGQ)
score, the freezing diary score or kinematic variables.
The UPDRS motor score was not improved (relative
to placebo) by MPD. In the study by Moreau et al, 69
patients suffering from severe PD (despite theOctober 2013optimization of drug treatments and STN stimulation
parameters) and FoG (subscores Z2 for item 14 of
FoGQ, UPDRS part II item 15 for gait in the “on”
condition and UPDRS part III item 30 for gait in the
“on levodopa” condition) were randomized 1:1 to
MPD or placebo for three months. As in Espay’s
study, improved gait (the number of steps in the SWS
test) was only observed in the “off-dopaminergic
drug” condition. However, FoG was less frequent in
the MPD group (relative to the placebo group) under
both “off-” and “on-dopaminergic drug” conditions.
The FoGQ score was lower in the MPD group than in
the placebo group. Interestingly, global motor func-
tion (ie the UPDRS III motor score) was slightly better
in the MPD group.
The disparities between the results obtained respec-
tively by Espay et al and Moreau et al. may be due to
differences in the study design (ie six months of follow-
up in Espay et al’s study, which increased the potential
for faster progression of axial signs than during the
three-month follow-up period in Moreau et al’s
study),51,52 the study population (the patients
in Moreau et al’s study were undergoing STN stimula-
tion)52 and the FoG assessment method (questionnaires
and an objective assessment in Moreau et al’s study vs
questionnaires and an electronic walkway (which might
not have elicited FoG sufﬁciently in Espay et al’s
study).51
In summary, administration of MPD in PD was
associated with improved gait in the open-label studies
and in the second (larger) double-blind, placebo-
controlled study.52 There were fewer motor symptoms
in the absence of levodopa and fewer FoG episodes
before and after an acute levodopa challenge. These
clinical beneﬁts had a positive impact on activities of
daily living and quality of life.52 Thus, MPD may be a
new therapeutic option for alleviating gait disorders with
FoG in PD patients undergoing. However, the long-term
risk/beneﬁt balance (especially in terms of the worsening
of axial signs and the potential cardiovascular risk in the
elderly) remains to be characterized.
Apathy
Dopaminergic apathy notably occurs in PD patients
undergoing STN stimulation after the tapering of
dopaminergic medications. The symptoms can be
relieved by the administration of dopamine ago-
nists.53,54 Chronic administration of high-dose MPD
(for three months) was associated with a signiﬁcant1643
Clinical Therapeuticsreduction in apathy (as measured on the Lille Apathy
Rating Scale (LARS)) in a subgroup of seven
advanced-stage PD patients undergoing STN stimula-
tion.52 However, the study was not speciﬁcally
designed to assess apathy. Methylphenidate (5 mg,
twice a day) also sharply reduced severe apathy in a
non-stimulated patient at an earlier stage of PD.55 In
conclusion, there are still too few data to draw ﬁrm
conclusions as to the value of MPD in apathy in PD -
although a beneﬁcial effect is plausible.
Attention and Cognitive Disorders
The various studies of MPD and cognitive function
have yielded conﬂicting results. Two open-label studies
showed a slight improvement in attention performance.
A reduction in simple reaction time was noted after
administration of a single, 20 mg dose of MPD to 21
patients.48 Memory and visuospatial performance
levels were unchanged.48 An improvement in
sustained attention was observed after three-month
course of MPD (1 mg/kg/d) in 10 non-demented
patients but not in 7 demented patients.50 However,
these results have not been conﬁrmed in randomized,
double-blind studies. In a study of ﬁve PD patients after
the withdrawal of antiparkinsonian medications, Ca-
micioli et al administered 0.2 mg/kg oral MPD or
placebo and (30 minutes later) a one-hour, intravenous
infusion of levodopa (2 mg/kg per hour) or placebo.
The researchers observed a lower choice reaction time
with MPD (relative to placebo) but failed to see any
effects on simple reaction time, attention and executive
function.56 The absence of a clear, beneﬁcial effect
of MPD on attention disorders in PD was recently
conﬁrmed in a double-blind, placebo-controlled,
randomized study of 69 patients.52 However, reaction
times have mainly been investigated as a secondary
efﬁcacy criteria in small patient populations and/or
under non-standardized conditions. Furthermore, dop-
aminergic treatment may have confounding effects.
Safety Concerns
Methylphenidate-associated adverse events have
been widely described in children (and, to a lesser
extent, adults) suffering from ADHD.57,58 The most
frequently reported events are gastrointestinal pain,
headaches and loss of appetite. In the PD population,
the safety proﬁle appears to be similar. Methylpheni-
date’s overall safety proﬁle is good.52,57 This may
partly have been due to good compliance with the1644contraindications, which mainly include psychiatric
and cardiac disorders.58,59 It has been reported that
confusion and hallucinations may arise in at-risk
populations, which requires the exclusion of PD
patients having previously suffered from hallucinations
and (possibly) demented patients. Another high psychi-
atric risk corresponds to mood modulation in patients
having already shown mania/bipolar disorder. Addic-
tion also represents a primary psychiatric contraindi-
cation. However, ICDs did not recur during MPD
treatment in patients who had experienced this type of
disorder while on dopaminergic agonists earlier in the
course of disease.52 It would be useful to test whether
MPD induces ICDs to a lesser extent that dopamine
agonists do. Lastly, cardiovascular adverse events may
be serious if the drug’s contraindications are not
rigorously observed - especially in view of the
advanced age of the PD population. In the largest
clinical trial to date, only mild, transient cardiovascular
adverse events were reported.52 The mean heart rate
increased signiﬁcantly (by three beats per minute) but
the blood pressure did not change signiﬁcantly in a
population with prevalent hypotension and
hypervariability related to dysautonomia. Hence (like
ADHD patients), PD patients should be closely
monitored, via six-monthly check-ups with a cardiol-
ogist58 or, at the very least, blood pressure and heart
rate monitoring every three months.59 There is a need
for long-term safety studies in this context.
POTENTIATING THE CHOLINERGIC SYSTEM
WITH ACETYL CHOLINESTERASE INHIBITORS
Cognitive Disorders
Patients with PD have particularly low cortical
levels of the neurotransmitter acetylcholine. It has
been shown that the use of cholinesterase inhibitors
to block acetylcholine breakdown may lead to clinical
improvements. The cholinesterase inhibitor rivastig-
mine is currently the only licensed treatment for
dementia in PD. Cochrane reviews have considered
the use of cholinesterase inhibitors in both PDD and
cognitive impairment in non-demented PD (CIND-
PD).60 The ﬁndings of four randomized, double-blind,
placebo-controlled trials support the use of cholines-
terase inhibitors in PDD,26,61–63 since they have a
positive impact on global assessment, cognitive func-
tion, behavioural disturbance and activities of daily
living. Cholinesterase inhibitors were more likely to
induce an adverse event as compared with placebo.Volume 35 Number 10
D. Devos et al.Tremor was reported more frequently in the treatment
group. Fewer deaths occurred in the treatment group
than in the placebo group. Only one study assessed
patients with CIND-PD.64 Although a positive impact
on the Mini-Mental State Examination score was
observed, there is no current evidence to support the
use of cholinesterase inhibitors in CIND-PD.
Apathy before Dementia
The neurochemical substrates of apathy have yet to
be unambiguously identiﬁed. Although several differ-
ent substrates are probably involved, the central
dopaminergic system’s role in reward and motivation
is often mentioned.33,65 Apathy can also occur in
patients with optimal dopaminergic regimens. Apathy
is more frequent in PD patients with cognitive decline
and may even precede dementia.31 Cummings and
Back suggested that medial frontal and limbic
cholinergic deﬁcits may underlie apathy in AD.66
This hypothesis is supported by the cholinesterase
inhibitors’ beneﬁcial effects on neuropsychiatric
symptoms (including apathy67). Hence, we reasoned
that cholinesterase inhibitors might compensate for
impaired cholinergic transmission within the limbic
and associative subcorticofrontal loops in PD. We
performed a multicentre, parallel, double-blind,
placebo-controlled, randomized clinical trial on
dementia-free patients with moderate-to-severe apa-
thy. Patients were randomly assigned 1:1 to a six-
month course of rivastigmine (a transdermal patch
delivering 9.5 mg/d) or placebo. The primary efﬁcacy
criterion was the change over time in the LARS score.
In all, 101 consecutive patients were screened, 31 were
eligible and 16 and 14 participants were randomized
into the rivastigmine and placebo groups, respectively.
Compared with placebo, rivastigmine was associated
with a better LARS score, a lower caregiver burden
and improvement in the Instrumental Activities of
Daily Living score. There were no serious adverse
events in the rivastigmine group.68 Rivastigmine may
represent a new therapeutic option for moderate-to-
severe apathy in advanced PD patients with optimized
dopaminergic treatment and who are free of depres-
sion and dementia. These ﬁndings require conﬁrma-
tion in a larger clinical trial.
Gait Disorders with Falls
Falling as a result of postural instability is a
signiﬁcant problem in advanced PD and is barelyOctober 2013impacted by dopaminergic therapy. Anticholinergic
medications increase the rate of falls in elderly
patients and demented patients. It has been hypothe-
sized that imbalance in the cholinergic pathways
might contribute to the increased risk of falls obser-
ved in PD. Loss of cholinergic neurons in the nucleus
basalis of Meynert and the pedunculopontine nucleus
(PPN) may have a directly, harmful effect on balance
and attention and may thus contribute to an increased
risk of falls. In a randomized, placebo-controlled,
cross-over trial in 23 PD patients with advanced
postural instability and who reported falling or nearly
falling more than twice a week, 10 mg of the centrally
acting cholinesterase inhibitor donepezil nearly
halved the frequency of falls. Subjects took six-week
courses of donepezil and placebo, with a 3-week
washout period between the two. The primary out-
come was the frequency of falls (as reported daily in a
study diary). The two phases did not differ signiﬁ-
cantly in terms of the frequency of near-falls or any
of the secondary outcomes (related to on balance,
cognition and motor handicap).69 Larger trials of cho-




Modulation of the glutamatergic system has mainly been
used to reduce levodopa-induced dyskinesia (LID). Des-
pite a low level of evidence, the N-methyl D-aspartate
(NMDA) receptor antagonist amantadine is considered
to have short-term beneﬁts in the treatment of LID and
remains widely used.70 Of the novel glutamatergic
molecules under development for the indication of
LID, AFQ056 (a selective metabotropic glutamate rece-
ptor 5 antagonist) has recently demonstrated antidys-
kinetic efﬁcacy without worsening underlying motor
symptoms. Pivotal phase III clinical trials are required
for licensing.71 Antiglutamatergic drugs (particularly
memantine (1-amino-3,5-dimethyladamantane), an un-
competitive, partial antagonist of the open NMDA rece-
ptor) have been also developed for the treatment of
cognitive disorders (mainly in AD).
Cognitive Disorders
Dementia with Lewy bodies (DLB) and PDD are
common forms of dementia. Recent evidence suggests
that memantine might be useful for treating PDD.72
However, the parallel-group, randomized, controlled1645
Clinical Therapeuticsstudies with memantine have yielded inconclusive
results. A ﬁrst 24-week, parallel-group, randomized,
controlled study of memantine (20 mg/d, n ¼ 34 pati-
ents) versus placebo (n ¼ 38 patients) showed better
clinical global impression of change scores (mean
difference: 0.7) and improved speed in attentional
tasks for the study drug.73 The second (larger) 24-
week, parallel-group, randomised, controlled study of
20 mg of memantine per day (n ¼ 34 patients with DLB
and 62 with PDD) versus placebo (n ¼ 41 patients with
DLB and 58 with PDD) found that the study drug was
associated with a greater improvement in global
cognitive status and behavioural symptoms for patients
with mild-to-moderate DLB but not for patients with
PDD.74 Memantine was well tolerated in both studies.
Hence, memantine might be an option for treatment of
DLB patients but it remains to be determined whether a
subgroup of PDD patients (perhaps those with severe
dementia) might beneﬁt from use of this drug.
Gait and Axial Disorders
Dopaminergic depletion induces glutamatergic hy-
peractivity in the brain in general and in the STN and its
efferent pathways projecting to the PPN in particu-
lar.75,76 The PPN is particularly involved in posture
and gait control.77 The NMDA receptor antagonist
MK-801 was found to facilitate locomotion in a rat
model of PD with bilateral PPN lesions.78 By decreasing
NMDA-dependant glutamatergic hyperactivity, mem-
antine reduces akinesia and rigidity in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model79
and improves locomotion in rats treated with reserpine
and alpha-methyl-p-tyrosine.80 A 90-day, randomized,
double-blind, pilot study of memantine (20 mg/d) versus
placebo (n ¼ 25 patients in total) did not ﬁnd a
signiﬁcant improvement in gait (in terms of the opto-
electronically measured stride length) but did evidence
signiﬁcant better results for the overall UPDRS score,
the latter’s axial subscore, the axial and overall
Dyskinesia Rating Scale scores, axial hypertonia and
axial strength (using an isokinetic dynamometer).81
Another double-blind, placebo-controlled study on a
small number of patients also failed to evidence a
beneﬁcial effect of intravenously administered amanta-
dine on dopamine-resistant FoG resistant.82 However, a
combination of memantine and L-dopa appeared to
be associated with a slight beneﬁcial effect on axial
motor handicap and LID in advanced PD patients with
severe axial symptoms.81 Memantine’s good safety1646proﬁle and its observed association with a lower
motor symptom score conﬁrmed the ﬁndings of two
open-label studies83,84 and two double-blind, placebo-
controlled studies.85,86 These beneﬁts must be conﬁr-




Most symptomatic treatments (and notably the
ones detailed here) were assessed in short-term clinical
trials in which the primary efﬁcacy criterion was the
intensity of a symptom or a syndrome. However, it
would be very interesting to consider the longer-term
progression of symptoms during treatment.
The Elldopa study showed that L-dopa (the most
efﬁcacious treatment of PD) may have neuroprotective
value. However, the study’s design prevented an analysis
of levodopa’s putative disease-modifying effect because of
the drug’s very long-lasting symptomatic beneﬁts. In the
ADAGIO study of an MAO-B inhibitor (rasagiline),
three hierarchical, co-primary endpoints were derived
from the rates of disease progression during deﬁned
treatment periods. Achievement of these co-primary
endpoints was equated with the presence of a disease-
modifying effect.87,88 Thus, one can hypothesize that all
dopaminergic medications may have disease-modifying
properties. However, the PROUD study did not observe
a disease-modifying effect for the dopaminergic agonist
pramipexole.89 However, MPD (which inhibits the DaT -
the most powerful determinant of extracellular dopamine
levels),45 may modify disease progression and should be
assessed as a putative DMT.
Cholinergic Disease Modifiers
Rivastigmine is licensed for the treatment of de-
mentia in PD. Whether these or other medications can
delay the progression from mild cognitive impairment
to dementia in PD is a key research question.72 In a
pilot study, apathetic PD patients treated over the
longer term had a slightly lower rate of dementia
occurrence than apathetic patients having received
short-term treatment did.68 However, the pilot
study’s design prevented a reliable analysis of this
topic but raised the question of whether the pre-
dementia initiation of rivastigmine (ie during apathy
in advanced PD or cognitive impairment in non-
demented PD patients) might have an effect on the
incidence of dementia.Volume 35 Number 10
D. Devos et al.Calcium Blockers
It has been nicely demonstrated that a calcium
blocker (which antagonizes calcium entry through
L-type channels) reduces the oxidative stress evoked
by pace-making in dopaminergic neurons.90 This
ﬁnding pointed the way to a novel neuroprotective
strategy in PD. A systematic Cochrane Collaboration
review noted that there is currently a lack of evidence
for the use of antihypertensive drugs in either primary
prevention (ie a lack of cohort studies and case-control
studies in PD-free participants) or secondary preven-
tion (ie a lack of clinical trials in patients with well-
deﬁned PD). The two cohort studies failed to observe
an association between exposure to calcium channel
blockers and the risk of developing PD. The results of
an on-going trial (examining the effects of the calcium
channel blocker isradipine on motor symptoms and
disease progression) should help inform further re-
search.91 A recent cohort study tested the effect of the
length of exposure to less brain-penetrant dihydropyr-
idines (amlodipine) and more brain-penetrant dihy-
dropyridines (eg nifedipine and felodipine) on
parkinsonism milestones (eg time to drug treatment
for parkinsonism, nursing home admission, and
death). In a population of 4733 hypertensive individ-
uals with parkinsonism, there were no signiﬁcant
differences between those taking amlodipine and those
taking other dihydropyridines. In summary, dihydro-
pyridine calcium channel blockers are unlikely to have
a clinically signiﬁcant effect on the course of PD.92
Peroxisome Proliferator-activated Receptor
(PPAR) Agonists
The PPAR is a member of a nuclear receptor
superfamily that regulates development, tissue differ-
entiation, inﬂammation, mitochondrial function,
wound healing, lipid metabolism and glucose metabo-
lism. Several PPAR agonists were shown to exert
neuroprotective activity against oxidative damage, in-
ﬂammation, and apoptosis in several neurodegenerative
diseases.93 Moreover, several epidemiological studies
have observed that regular intake of PPAR-activating,
non-steroidal anti-inﬂammatory drugs (such as indo-
methacin and ibuprofen) was associated with a lower
incidence and slower progression of neurodegenerative
diseases (including PD).93 A retrospective study of 419
patients showed a possible disease-modifying effect of
ﬁbrate and statin PPAR agonists.94 A recent, large,
prospective study has demonstrated that regular use ofOctober 2013statins is associated with a modest reduction in the PD
risk.95 Of course, these drugs are pleiotropic and the
putative beneﬁcial effect in PD may not be solely
related to PPAR activation. It has been shown that
PPAR-gamma agonists are neuroprotective in animal
models; pioglitazone is active in MPTP and 6-
hydroxydopamine rodent model96 and rosiglitazone is
active in MPPþ SH-SY5Y cells.97 This preclinical
evidence have the assessment of pioglitazone in a
Phase II clinical trial in early PD patients. Many
currently licensed drugs modulate the PPAR and thus
could be assessed as DMTs.
It is interesting to note that the thiazolidinediones
(including rosiglitazone and pioglitazone) target iron-
sulphur cluster proteins in mitochondria and the
endoplasmic reticulum; these proteins have vital roles
in cell energetics, apoptosis and autophagy.98
Iron Chelators
Iron metabolism is a tightly regulated process that is
designed to render iron available for biochemical
functions while minimizing the metal’s involvement
in harmful radical formation.99 In various inherited
and acquired disorders, the cell’s iron-storage mecha-
nisms and antioxidant capacities are overwhelmed by
misdistribution of iron and ensuing reactive oxygen
species (ROS) formation and oxidative damage.99–101
The biological damage associated with siderosis mostly
results from a rise in labile iron, which is comprised
of redox-active and chelatable forms of the metal. In
PD, excess iron is detected primarily in the substantia
nigra pars compacta (SNc),102–106 where dopaminergic
neurons are exposed to high ROS levels93,106–108
produced by the metabolism of dopamine.109,110 It
has been recently demonstrated that iron chelation
with deferiprone (a membrane-permeant, bidentate
chelators with putative neuroprotective properties in
Friedreich’s ataxia111) signiﬁcantly reduced labile iron
levels and biological damage in oxidation-stressed cells
and improved motor functions while raising striatal-
dopamine levels in animal models. In a prospective,
placebo-controlled study of early-stage PD patients
with stable dopaminergic regimens, early-start (n ¼
19) patients compared to responded signiﬁcantly ear-
lier (and for longer) to deferiprone treatment (relative
to delayed-start patients) in terms of brain R2* MRI
sequences (indirectly reﬂecting iron agglomerates in the
SNc) and the UPDRS score. Apart from three rapidly
resolved cases of iatrogenic neutropenia, safety was1647
Clinical Therapeuticsmaintained throughout the trial and no systemic metal
loss was observed - despite uninterrupted daily treat-
ment for up to 18 months.112 The therapeutic features
of this novel chelation modality (established in
translational models and assessed in a pilot clinical
trial based on a delayed-start paradigm) warrant a
comprehensive evaluation in PD.
CONCLUSION
In advanced PD patients undergoing STN stimulation,
the potentiation of noradrenergic and dopaminergic
transmission with MPD improved gait and FoG and
may relieve apathy; however, the drug failed to
improve cognition in this population. Potentiation of
the cholinergic system with acetylcholinesterase inhib-
itors (which are licensed for the indication of demen-
tia) may partially relieve pre-dementia apathy and
reduce the risk of the falls. These ﬁndings require
conﬁrmation in a larger clinical trial. Modulation of
the glutamatergic system with NMDA receptor antag-
onists did not improve gait and dementia but may
have improved axial rigidity. Dopamine and/or nora-
drenaline transporter inhibitors, anticholinesterase in-
hibitors, PPAR agonists and iron chelators should be
investigated as putative DMTs in a delayed-start
paradigm trial in a large population.
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